Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.42 |
| ▸ | LPL | P06858 | 10/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696743 | 0.86 | LPL (0.40) | LIPGLPLF11ESR2UCHL1 | |
| SCHEMBL22982573 | 0.85 | LPL (0.39) | LIPGLPLF11ESR2UCHL1 | |
| SCHEMBL29531067 | 0.85 | LPL (0.39) | LIPGLPLF11ESR2UCHL1 | |
| SCHEMBL258023 | 0.85 | LPL (0.39) | LIPGLPLF11ESR2UCHL1 | |
| SCHEMBL14694384 | 0.82 | LPL (0.37) | LIPGLPLF11UCHL1 | |
| SCHEMBL7248939 | 0.82 | LIPG (0.42) | LIPGLPLF11ESR2UCHL1 | |
| SCHEMBL104247 | 0.76 | LPL (0.65) | LIPGLPLF11ESR2 | |
| SCHEMBL3039403 | 0.74 | LIPG (0.63) | LIPGLPLF11ESR2ANPEP | |
| SCHEMBL14696474 | 0.74 | LIPG (0.41) | LIPGLPLF11 | |
| SCHEMBL1075777 | 0.73 | LPL (0.41) | LIPGLPLF11ESR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630577-B2 | Useful for producing bioconjugates | PROLINX, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1264833-A2 | 1,2-Phenylenediboronic acid reagents and complexes | PROLINX, INC. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020038004-A1 | 1,2-phenylenediboronic acid reagents and complexes | PROLINX, INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038004-A1 | 1,2-phenylenediboronic acid reagents and complexes | BCR, MGST1, SULT1E1 | LIPG 3653/4885LPL 4435/4885F11 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.